

# Frequency of Restless Legs Syndrome among End-Stage Renal Disease Patients on Maintenance Hemodialysis

Restless Legs Syndrome among End-Stage Renal Disease

Sumaira Ishaq<sup>1</sup>, Shahid Anwar<sup>1</sup>, Mateen Akram<sup>2</sup>, Sajad Ahmad<sup>1</sup>, Hafiz Tahir Usman<sup>1</sup> and Zahid Anwar<sup>3</sup>

## ABSTRACT

**Objective:** To determine the frequency of restless leg syndrome among patients of end-stage renal disease undergoing hemodialysis.

**Study Design:** Cross-sectional study

**Place and Duration of Study:** This study was conducted at the Department of Nephrology Department, Ganga Ram Hospital, Lahore from 20<sup>th</sup> October 2019 to 20<sup>th</sup> April 2020.

**Materials and Methods:** One hundred and sixty patients on hemodialysis were enrolled. Patients were assessed for age, gender, body mass index, presence of hypertension, diabetes, anemia, and RLS as per operational definition.

**Results:** 98 (60.5%) were male patients and 64 (39.5%) were female patients, 37% were from the age group of 18-40 years, 35 patients (21.6%) were having an iron deficiency, 151(93.2%) were hypertensive, 59(36.4%) were diabetic, 45(27.8%) were on antipsychotic/antidepressant drugs and 21(13%) were using antihistamines. 85 patients (52.5%) were having RLS. Among 45 patients who were on antipsychotics/antidepressants, 31 (68.9%) were having RLS with statistical significance (p-value 0.009). Among 21 patients who were on antihistamines, 19(90.5%) were having RLS with a statistically significant p-value of 0.00018. Among iron deficient patients 35(21.6%), 16(45.7%) were having RLS and 19(54.3%) were not exhibiting RLS symptoms, showed no statistically significant difference (p-value 0.366).

**Conclusion:** The frequency of Restless Legs Syndrome is 52.5% among end-stage renal disease patients on maintenance hemodialysis.

**Key Words:** Restless leg syndrome, End-stage renal disease, Hemodialysis

**Citation of article:** Ishaq S, Anwar S, Akram M, Ahmad S, Usman HT, Anwar Z. Frequency of Restless Legs Syndrome among End-Stage Renal Disease Patients on Maintenance Hemodialysis. Med Forum 2022;33(2):138-141.

## INTRODUCTION

Unpleasant sensation in lower limbs that compels the individual to sway his legs, is a neurological pathology often termed as Restless legs syndrome (RLS)<sup>1</sup>. These feelings are often explained by patients as creepy, pin pricking, stretching, or distressing sensation in lower limb muscles. These feelings tend to worsen at night time especially during sleep and movements of legs help in overcoming these symptoms.

<sup>1</sup>. Department of Nephrology, Fatima Jinnah Medical University/Sir Ganga Ram hospital, Lahore.

<sup>2</sup>. Department of Nephrology, Shaikh Zayed Postgraduate Medical Institute Lahore.

<sup>3</sup>. Department of Pediatrics, Fatima Memorial Hospital and Medical College, Lahore.

Correspondence: Dr. Sumaira Ishaq, Medical officer, Nephrology Department, Fatima Jinnah Medical University/Sir Ganga Ram hospital, Lahore.

Contact No: 0332-4168050

Email: dr\_sumaira111@hotmail.com

Received: July, 2021

Accepted: December, 2021

Printed: February, 2022

RLS follows a specific day and night cycle, the appearance of symptoms occurs in the evening and becomes severe during nighttime sleep, whereas little or no symptoms occur during daytime.<sup>2</sup>

Fluctuation in the severity of these symptoms persists lifelong and complete resolution is rarely seen.<sup>3</sup>In many cases no cause has been identified hence called idiopathic RLS, whereas it could be secondary to some systemic diseases like anemia, peripheral sensory neuropathy, Diabetes, and thyroid disorders. It has been observed in alcoholic individuals and pregnant females as well.<sup>4</sup> A significant proportion of chronic kidney disease (CKD) patients experience these symptoms. RLS is one of the chief problems of hemodialysis (HD) patients reported to nephrologists. Maintenance HD is a lifelong therapeutic option for end-stage renal disease (ESRD) patients, which not only brings financial constraints, reduction in physical and mental wellbeing, altered sleep patterns, and severe depression. RLS is frequently observed in patients with the HD-induced ailments.<sup>5</sup>

RLS is also considered a part of sleep disorder as it augments insomnia, poor sleep quality, interrupted sleep, and reduced sleep duration. Lack of normal sleep, in turn, augments anxiety, depression, and

deterioration in overall quality of life.<sup>6</sup> It has been observed that an increase in cardiovascular accidents and nocturnal hypertension is strongly associated with RLS-induced sleep disorders.<sup>7</sup>

RLS incidence of 5–15% is documented in the normal population.<sup>7</sup> Hallmark REST trial (RLS epidemiology symptoms and treatment) conducted in 2014 among 23 thousand normal individuals showed an 11.9% prevalence of RLS.<sup>8</sup> In Pakistani study conducted by Khalid M, et al reported 23.6% prevalence in the general population.<sup>9</sup> As compared to the normal population, the prevalence in CKD patients is around 24.2% and, the prevalence in HD patients is 35.5–40.7%. RLS prevalence varies from country to country, the lowest reported incidence is 17% whereas the highest is 62%.<sup>10</sup> In Pakistani HD patients prevalence is 24%.<sup>11</sup>

The pathophysiology of RLS is complex and multiple abnormalities play a crucial role in the development and severity of RLS. Endothelial cells at the blood-brain barrier act at storage sites of iron for the brain, in iron-deficient states uptake of iron by neurons is reduced resulting in altered neuronal dopaminergic function. This signifies the role of iron deficiency anemia in the development of RLS.<sup>12</sup> Apart from iron deficiency, structural and functional abnormalities in central or peripheral dopamine-producing neurons have been observed in the uremic milieu among CKD and HD patients.<sup>13</sup> The presence of RLS in other family members signifies the role of genetic defects. Females and longer duration on HD were linked to the severity of RLS documented by different studies.<sup>10</sup>

Although multiple studies have been conducted to explore RLS in HD patients worldwide, there is a lot of variation in results especially in its burden and confounding factors. The results of this study will help us to understand the frequency of RLS in our population and it will help in the early recognition and treatment of the patients suffering from RLS.

## MATERIALS AND METHODS

This cross-sectional study was conducted in Nephrology Department, Ganga Ram Hospital, Lahore, from October 20, 2019, to April 20, 2020. The sample size of 162 was estimated by using a 95% confidence level with a 5% margin of error and taking an expected percentage of RLS as 12.4% in ESRD patients undergoing hemodialysis.<sup>9</sup> Patients of both gender, ages between 18–70 years who were on HD for at least 3 months were included. Patients having acute kidney injury, musculoskeletal disorders, recent myocardial infarction or unstable angina, any catabolic process were excluded from the study. After approval of the Hospital Ethical Committee, written informed consent, demographic information was recorded. Patients were assessed for age, gender, body mass index, presence of hypertension, diabetes, smoking, and anemia. RLS was

assessed using the International Restless Leg Syndrome Study Group rating scale.<sup>14</sup>

Data were entered and analyzed using SPSS-25.0. For post-stratification, a Chi-square test was applied to see the significance. A p-value  $\leq 0.05$  was considered significant.

## RESULTS

There were 98 (60.5%) male patients and 64 (39.5%) female patients. Among these patients 37% were from the age group of 18–40 years, 63% were from the age group 41–70 years. Among these patients, 43.8% had BMI > 25 and 56.2% had BMI between 18–25.

**Table No.1: Stratification of gender, age, diabetes, hypertension, iron deficiency, BMI, HD duration, antidepressants and antihistamines according to RLS (n=162)**

RLS (n=102)			
Variable	RLS		P value
	Yes	No	
Gender			
Male	45 (45.9%)	53 (54.1%)	0.039
Female	40 (62.5%)	24 (37.5%)	
Age (years)			
18-40	28 (46.7%)	32 (53.3%)	0.257
41-70	57 (55.9%)	45 (44.1%)	
Diabetes			
Yes	32 (54.2%)	27 (45.8%)	0.733
No	53 (51.5%)	50 (48.5%)	
Hypertension			
Yes	78 (51.7%)	73 (48.3%)	0.442
No	7 (63.6%)	4 (36.4%)	
Iron Deficiency			
Yes	16 (45.7%)	19 (54.3%)	0.366
No	69 (54.3%)	58 (45.7%)	
BMI			
Low or normal	44 (48.4%)	47 (51.8%)	0.235
Overweight	41 (57.75)	30 (42.35)	
HD Duration			
6-12 Months	2 (25%)	6 (75%)	0.051
1-3 Years	26 (66.7%)	13 (33.3%)	
>3 Years	57 (49.6%)	58 (50.4%)	
Antidepressants			
Yes	31 (68.9%)	14 (31.1%)	0.009
No	54 (46.2%)	63 (53.8%)	
Antihistamines			
Yes	19 (90.5%)	2 (9.5%)	0.00018
No	66 (46.8%)	75 (53.2%)	

Among them, 4.9% were on MHD for 6–12 months, 24.1% for 1–3 years, and 71.0% for >3 years. 35 patients (21.6%) were having an iron deficiency, 151 (93.2%) were hypertensive, 59 (36.4%) were diabetic, 45 (27.8%) were on antipsychotic/antidepressant drugs and 21 (13%) were using antihistamines. Our study showed

that 85 patients (52.5%) were having RLS. Eighty five patients (52.5%) were having RLS. On stratification of RLS with age, 46.7% were having RLS in 18-40 years age group, and 55.9% in 41-70 years age group, with no statistical significance (p-value 0.257). In our study group, among 98 male patients, 45.9% (45) were having RLS & among 64 female patients, 62.5% (40) were having RLS, with statistical significance (p-value 0.039). Among 59 diabetics, 32(54.2%) were having RLS and among 151 hypertensives 51.7% were having RLS without any statistical significance (p-value 0.733, 0.442 respectively). Among 91 patients who have (BMI 18-25) 44 patients (48.41%) were having RLS and 71 patients (BMI >25), 41 (57.7%) were having RLS without any statistical significance (p-value 0.235). Among these 8 patients who were on HD for 6-12 months, 2(25%) were having RLS, and among 39 pts who were on HD for 1-3 years, 26(66.7%) was having RLS and among 115 pts who were on HD for >3 years, 57 (49.6%) were having RLS without any statistical significance (p-value 0.051). Among 45 patients who were on antipsychotics/antidepressants, 31 (68.9%) were having RLS with statistical significance (p-value 0.009). Among 21 patients who were on antihistamines, 19(90.5%) were having RLS with a statistically significant p-value of 0.00018. Among Iron deficient patients 35(21.6%), 16(45.7%) were having RLS and 19(54.3%) were not exhibiting RLS symptoms, showed no statistically significant difference (p-value 0.366) (Table 1).

## DISCUSSION

Diagnosis of RLS depends upon the presence of four symptoms as proposed by the International RLS Study Group, that includes: (1) unpleasant sensation in legs that produces a desire to move legs, (2) occurring in resting state, (3) resolved by legs movements, and (4) exhibiting circadian rhythm with maximum symptoms appearance at night. But these symptoms must be differentiated from other closely related clinical conditions that can mimic RLS. These disorders are leg cramps, peripheral sensory neuropathy, arthritis, habitual leg movements, and sleeping position discomfort. It has been seen that these 4 criteria demonstrate a positive predictive value of <50% in the general population whereas the specificity of 84% is present in RLS patients.<sup>15</sup>

In different studies done all over the world the frequency of RLS in the general population is reported to be between 20 to 25%,<sup>16</sup> and in patients of ESRD on HD is 23.3 to 38%.<sup>17,18</sup> Our study showed 52.5% of patients have RLS. There could be three major reasons for this variable reports of RLS frequency, first the genetic heterogeneity of the different study groups population, second the difference in diagnostic criteria and tools used for RLS, third and the most important, the presence or absence of confounding factors that can

precipitate RLS. Studies have proved that genetic factors play an important role in the pathogenesis of RLS and autosomal dominant pattern in familial RLS has been observed in Canada, Italy, and France.<sup>19</sup> The frequency of RLS was 52.5% in our study as compared to 26% in the Indian population,<sup>20</sup> 33% in the Japanese population,<sup>21</sup> 20-50% in the Saudi population,<sup>22</sup> and 14-21% in Caucasians.<sup>23</sup> Different scoring scales for RLS are IRLSSG diagnostic criteria (International Restless Legs Syndrome Study Group)<sup>24</sup>, RLS-6 scale, JHRLSSS (John Hopkins RLS Severity Scale), and the investigator-based CGI (Clinical Global Impressions).<sup>7</sup> Diversity in these diagnostic tools can be a contributing factor for diverse RLS prevalence studies results.

In our study females are affected more as compared to male patients, possibly due to hormonal differences in both genders.<sup>25</sup> Advanced age is also considered as a risk factor for an idiopathic class of RLS. However, some researchers proved that this link between old HD patients and RLS is not always present.<sup>25</sup> In our study advancing age does not affect RLS frequency. Several studies have proved increased RLS occurrence in iron deficiency anemia<sup>10</sup> but in our study, no statistically significant correlation is found. The presence of depression and use of antidepressants has been linked to increased severity of RLS,<sup>26</sup> likewise in our patient's use of antidepressants showed more prevalent RLS. Links have been proved between antihistamine use and RLS as shown in our study as well.<sup>27</sup>

## CONCLUSION

The frequency of Restless Legs Syndrome is 52.5% among end-stage renal disease patients on maintenance hemodialysis.

### Author's Contribution:

Concept & Design of Study:	Sumaira Ishaq
Drafting:	Shahid Anwar, Mateen Akram
Data Analysis:	Sajad Ahmad, Hafiz Tahir Usman, Zahid Anwar
Revisiting Critically:	Sumaira Ishaq, Shahid Anwar
Final Approval of version:	Sumaira Ishaq

**Conflict of Interest:** The study has no conflict of interest to declare by any author.

## REFERENCES

1. de Menezes AF, Motta DRM de S, de Carvalho FO, Santana-Santos E, de Andrade Júnior MP, Figueirôa MF, et al. Restless legs syndrome in dialysis patients: does the dialysis modality influence its occurrence and severity? *Int J Nephrol* 2018; 2018:1414568.

2. Einollahi B, Izadianmehr N. Restless leg syndrome: a neglected diagnosis. *Nephrourol Mon* 2014; 6(5): e22009.
3. de Oliveira MM, Conti CF, Valbuza JS, de Carvalho LBC, do Prado GF. The pharmacological treatment for uremic restless legs syndrome: evidence-based review. *Mov Disord* 2010;25(10): 1335–42.
4. Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG. Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. *Mayo Clin Proc* 2013;88(9):977–86.
5. Dauvilliers Y, Benes H, Partinen M, Rauta V, Rifkin D, Dohin E, et al. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. *Am J Kidney Dis* 2016;68(3):434–43.
6. Breen DP, Högl B, Fasano A, Trenkwalder C, Lang AE. Sleep-related motor and behavioral disorders: Recent advances and new entities. *Mov Disord* 2018;33(7):1042–55.
7. Nagandla K, De S. Restless legs syndrome: pathophysiology and modern management. *Postgrad Med J* 2013;89(1053):402–10.
8. Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. *Sleep Med* 2004;5(3):237–46.
9. Mahmood K, Farhan R, Surani A, Surani AA, Surani S. Restless Legs Syndrome among Pakistani Population: A Cross-Sectional Study. *Int Sch Res Notices* 2015;2015:762045.
10. Guo S, Huang J, Jiang H, Han C, Li J, Xu X, et al. Restless Legs Syndrome: From Pathophysiology to Clinical Diagnosis and Management. *Front Aging Neurosci* 2017;9:171.
11. Ul Abideen Z, Mahmud SN, Mushtaq F, Farooq MU, Farooq Qasim Y, Hamid Z, et al. Association of Hemodialysis Inadequacy and Duration with Restless Legs Syndrome: a Cross-sectional Study. *Cureus* 2018;10(5):e2570.
12. Trotti LM, Becker LA. Iron for the treatment of restless legs syndrome. *Cochrane Database Syst Rev* 2019;1:CD007834.
13. Rocchi C, Albanese M, Placidi F, Romigi A, Lauretti B, Marfia GA, et al. Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system? *Sleep Med* 2015; 16(9):1071–6.
14. Gupta R, Lahan V, Goel D. Translation and validation of International Restless Leg Syndrome Study Group rating scale in Hindi language. *Ann Indian Acad Neurol* 2011;14(4):257–61.
15. Hening WA, Allen RP, Washburn M, Lesage SR, Earley CJ. The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions (“mimics”). *Sleep Med* 2009;10(9): 976–81.
16. Nichols DA, Allen RP, Grauke JH, Brown JB, Rice ML, Hyde PR, et al. Restless Legs Syndrome Symptoms in Primary Care: A Prevalence Study. *Arch Internal Med* 2003;163(19):2323–9.
17. Xiao C, Liang X, Li R, Cai L, Xu D. [A cross-sectional study of restless legs syndrome in maintenance hemodialysis patients]. *Zhonghua Nei Ke Za Zhi* 2013;52(8):672–4.
18. Kim J-M, Kwon H-M, Lim CS, Kim YS, Lee S-J, Nam H. Restless Legs Syndrome in Patients on Hemodialysis: Symptom Severity and Risk Factors. *J Clin Neurol* 2008;4(4):153–7.
19. Dhawan V, Ali M, Chaudhuri KR. Genetic aspects of restless legs syndrome. *Postgrad Med* 2006; 82(972):626–9.
20. Bhowmik D, Bhatia M, Gupta S, Agarwal SK, Tiwari SC, Dash SC. Restless legs syndrome in hemodialysis patients in India: a case controlled study. *Sleep Med* 2003;4(2):143–6.
21. Kawauchi A, Inoue Y, Hashimoto T, Tachibana N, Shirakawa S, Mizutani Y, et al. Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. *Clin Nephrol* 2006;66(6):440–6.
22. Al-Jahdali HH, Al-Qadhi WA, Khogeer HA, Al-Hejaili FF, Al-Ghamdi SM, Al Sayyari AA. Restless legs syndrome in patients on dialysis. *Saudi J Kidney Dis Transpl* 2009;20(3):378–85.
23. Araujo SMHA, de Bruin VMS, Nepomuceno LA, Maximo ML, Daher E de F, Correia Ferrer DP, et al. Restless legs syndrome in end-stage renal disease: Clinical characteristics and associated comorbidities. *Sleep Med* 2010;11(8):785–90.
24. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. *Sleep Med* 2014;15(8):860–73.
25. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. *Neurol* 2000; 54(5):1064–8.
26. Koo BB, Blackwell T, Lee HB, Stone KL, Louis ED, Redline S, et al. Restless Legs Syndrome and Depression: Effect Mediation by Disturbed Sleep and Periodic Limb Movements. *Am J Geriatr Psychiatry* 2016;24(11):1105–16.
27. Bliwise DL, Zhang RH, Kutner NG. Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS). *Sleep Med* 2014;15(10):1241–5.